This multicenter study evaluates the effectiveness and safety of a 12-week regimen of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C who relapsed after prior direct-acting antiviral therapy. The study assesses the rate of sustained virologic response after treatment, along with changes in liver function and overall safety. It also explores whether clinical factors such as liver cirrhosis, viral genotype, and the use of ribavirin influence treatment outcomes, aiming to better define this regimen as a salvage therapy option.
Eligibility
Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria:
1. Age ≥18 years at the time of enrollment
2. Confirmed chronic hepatitis C virus (HCV) infection
3. Documented virologic relapse after prior direct-acting antiviral (DAA) therapy
4. Detectable HCV RNA at screening
5. Received or planned to receive a 12-week regimen of sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) as salvage therapy
6. Willing and able to provide written informed consent
Exclusion Criteria:
1. Pregnant or breastfeeding women
2. Participation in another interventional clinical study during the study period
Primary outcome measure(s)
Sustained Virologic Response at 12 Weeks After Treatment (SVR12) — 12 weeks after end of treatment Proportion of participants with undetectable HCV RNA 12 weeks after completion of treatment.
Trial sites (1)
Facility
City
Region
Status
Xiangya Hospital of Central South University
Changsha
Hunan
More Xiangya Hospital of Central South University trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.